Clinical Trial Search

Primary: Number of Participants With Adverse Events — 3 Participants

Primary: The Primary Objective is to Evaluate the Safety of Prostate Artery Embolization (PAE) for the Treatment of Lower Urinary Tract Symptoms (LUTS) Attributed to Benign…

Primary: Number of Adverse Events Reported — 7 adverse events

Primary: Number of Reported Treatment-related Adverse Events (AE) as Assessed by NCI CTCAE Grading Scale . — 6; 10; 0; 0 events — p=0.05

Primary: Number of Participants With Bladder or Rectal Injury — 0 Participants

Primary: International Prostate Symptom Score (IPSS) Change — -17.5 units on a scale

Primary: At 6 Months, the 95% Lower Confidence Limit of the Mean Percent Improvement in IPSS Over Baseline for the UroLift System Must be ≥ 25%. — 57.7 percent change

Primary: Change in International Prostate Symptom Scale (IPSS) of Lower Urinary Tract Symptoms From Baseline to 3 Months (Total Score at 3 Months Minus Total Score at Baseline)…

Primary: International Prostate Symptom Score (IPSS) — -6.2; -5.1; -5.7 Units on a scale — p=0.371

Primary: Number of Men With Confirmed Diagnosis of BPH — 386; 437 Participants

Primary: Negative Biopsy Rate at 6 Months After Focal Bipolar Radio-Frequency Ablation (RFA) — 3; 2; 1 Participants

Primary: The Area of the Transperineal Targeted Microwave Ablation (TMA) Induced Tissue Death Assessed by Triphenyltetrazolium Chloride (TTC) Staining

Primary: Prostate Tissue DHT — 0.03; 0.06; 0.03 ng/g

Primary: Mean Change in IPSS Score — -11.4 units on a scale

Primary: Number of Participants Reporting Compliance With Medication — 239; 161 participants

Primary: Change in Extent of Cancer — 3; 2; 4 participants

Primary: Median Tumor Volume Burden at Baseline Multi-parametric Magnetic Resonance Imaging (mpMRI) Before and After Surgery — 3.44; 0.62 cc

Primary: Incidence of Clavien-Dindo Adverse Events (Percentage of Participants) Through 3 Months Post Treatment — 45.5 percentage

Primary: IPSS Change From Baseline — -5.6 Units on a scale — p=<0.001

Primary: Number of Events of Acute Urinary Retention (AUR) or Benign Prostatic Hyperplasia (BPH)-Related Prostatic Surgery at the Indicated Time Periods. — 29; 27; 40; 14 events…

Primary: Combined pCR or MRD Rate [Part 1] — 12; 12 Participants

Primary: Number of Participants With Biochemical Failure at 5 Years — 0; 30 Participants

Primary: Number of Participants With Risk of Acute Urinary Retention and Surgery Based on an MPR Threshold of 70% — 2140; 1587; 481; 331 participants

Primary: Number of Participants With Clinical Progression — 14; 5 participants — p=0.0128

Primary: Mean Prostate Specific Antigen (PSA) Level — 0.61; 0.70; 0.54 ng/mL

Primary: Successful Trial Without Catheter Peri-procedurally — 29; 0 Participants

Primary: PET Biomarker Uptake — 0.95; 0.98 Standard Uptake Measure SUV

Primary: Change in Number of Subjects With Adverse Events Will be Collected — 22; 18; 17 Participants

Primary: Number of Lesions With Gleason Score ≥ 7 Identified by Ultrasound Molecular Imaging — 17; 8 number of lesions

Primary: International Prostate Symptom Score (IPSS) Change From Baseline — -0.4; -5.0; -13.1; -12.6 score on a scale